Company profilePharmaceutical#648 of 1,318 in Pakistan✓ No DRAP alerts

Orbis Pharmaceuticals

Pharmaceutical company · 16 brands · 10 molecules

16 registered products 20 pharmaceutical brands 10 distinct molecules 0 DRAP alerts

Company overview

16
registered products
20
pharmaceutical brands
10
distinct molecules
0
therapeutic classes
0
DRAP alerts

Orbis Pharmaceuticals is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 16 product registrations across 10 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Orbis

12 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

10
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202510

Top molecules by brand count

Quetiapine5 brands
Risperidone5 brands
Azithromycin3 brands
Azithromycin ...... 200 Mg1 brand
Quetiapine ...... 100 Mg1 brand
Quetiapine ...... 25 Mg1 brand
Quetiapine ...... 150 Mg1 brand
Quetiapine ...... 50 Mg1 brand
Quetiapine ...... 300 Mg1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official20 products · Rs 237.88 – Rs 3,938.92
Median across source: Rs 594.7

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

HIGH - Q INTERNATIONAL7 shared molecules
AGP (PRIVATE) LTD.7 shared molecules
BIO LABS (PVT) LTD.6 shared molecules
DONVALLEY6 shared molecules
ARP (PVT) Limited6 shared molecules
HILTON PHARMA (PVT) LIMITED6 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

HIGH - Q INTERNATIONAL holds 138 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAmikacinAmlodipineAnastrozoleAprepitant
Werrick Pharmaceuticals Pakistan holds 137 molecules not in this portfolio
AcetazolamideAlendronateAlprazolamAmlodipineAmoxicillinAmoxycillin
AGP (PRIVATE) LTD. holds 141 molecules not in this portfolio
AmikacinAminophyllineAmlodipineAmoxicillinAprepitantArtemether

Get the full profile for Orbis

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.